C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy

Brain, Behavior, and Immunity

Volumn 34, Issue , 2013, Pages 108-119

  Pertl, Maria M ^a   Hevey, David ^a   Boyle, Noreen T ^a   Hughes, Martina M ^a   Collier, Sonya ^b   O'Dwyer, Anne Marie ^b   Harkin, Andrew ^a   Kennedy, M John ^b   Connor, Thomas J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cancer; Cancer related fatigue; CRP; Cytokine; Depression; IFN ; IL 6; Inflammation; Kynurenine; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 6; KYNURENINE; PACLITAXEL; TRASTUZUMAB; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MASTECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRYPTOPHAN METABOLISM; WIDE EXCISION;

CANCER; CANCER-RELATED FATIGUE; CRP; CYTOKINE; DEPRESSION; IFN-Γ; IL-6; INFLAMMATION; KYNURENINE; TNF-Α;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CYTOKINES; DEPRESSION; FATIGUE; FEMALE; HUMANS; INFLAMMATION; KYNURENINE; MIDDLE AGED; TRYPTOPHAN;

EID: 84885050941     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.07.177     Document Type: Article

References (75)

1. Agasi-Idenburg C., Velthuis M., Wittink H. Quality criteria and user-friendliness in self-reported questionnaires on cancer-related fatigue: a review. J. Clin. Epidemiol. 2010, 63:705-711.
2. Alexander S., Minton O., Stone P.C. Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors. J. Clin. Oncol. 2009, 27:1197-1201.
3. Amori L., Wu H.Q., Marinozzi M., Pellicciari R., Guidetti P., Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 2009, 159:196-203.
4. Barsevick A., Frost M., Zwinderman A., Hall P., Halyard M. I'm so tired: Biological and genetic mechanisms of cancer-related fatigue. Quality Life Res. 2010, 19:1419-1427.
5. Berger A.M., Wielgus K., Hertzog M., Fischer P., Farr L. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support. Care in Cancer 2010, 18:105-114.
6. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J. Psychosom. Res. 2002, 52:69-77.
7. Bower J.E., Lamkin D.M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 2013, 30:S48-S57.
8. Bower J.E., Ganz P.A., Lin Tao M., Hu W., Belin T.R., Sepah S., Cole S., Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15:5534-5540.
9. Brown L.F., Rand K.L., Bigatti S.M., Stewart J.C., Theobald D.E., Wu J., Kroenke K. Longitudinal relationships between fatigue and depression in cancer patients with depression and/or pain. Health Psychol. 2012, http://dx.doi.org/ 10.1037/a0029773. [Epub ahead of print].
10. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
11. Cameron B.A., Bennett B., Li H., Boyle F., deSouza P., Wilcken N., Friedlander M., Goldstein D., Lloyd A.R. Post-cancer fatigue is not associated with immune activation or altered cytokine production. Ann. Oncol. 2012, 23:2890-2895.
12. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
13. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54:906-914.
14. Chen Y., Guillemin G.J. Kynurenine pathway metabolites in humans: disease and healthy states. Int. J. Tryptophan Res. 2009, 2:1-19.
15. Cryan J.F., Leonard B.E. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum. Psychopharmacol. 2000, 15:113-135.
16. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
17. Elshal M.F., McCoy J.P. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006, 38:317-323.
18. Fagundes C.P., Glaser R., Alfano C.M., Bennett J.M., Povoski S.P., Lipari A.M., Agnese D.M., Yee L.D., Carson Iii W.E., Farrar W.B., Malarkey W.B., Kiecolt-Glaser J.K. Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav. Immun. 2012, 26:394-400.
19. Fossa S.D., Dahl A.A., Loge J.H. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 2003, 21:1249-1254.
20. Fu Q., Zhu J., Van Eyk J.E. Comparison of multiplex immunoassay platforms. Clin. Chem. 2010, 56:314-318.
21. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999, 340:448-454.
22. Gimeno D., Kivimäki M., Brunner E., Elovainio M., De Vogli R., Steptoe A., Kumari M., Lowe G., Rumley A., Marmot M., Ferrie J. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol. Med. 2009, 39:413-423.
23. Haghighat S., Akbari M.E., Holakouei K., Rahimi A., Montazeri A. Factors predicting fatigue in breast cancer patients. Support. Care Cancer 2003, 11:533-538.
24. Hofman M., Ryan J.L., Figueroa-Moseley C.D., Jean-Pierre P., Morrow G.R. Cancer-related fatigue: the scale of the problem. Oncologist 2007, 12:4-10.
25. Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T., Connor T.J. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav. Immun. 2012, 26:979-987.
26. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
27. Jager A., Sleijfer S., van der Rijt C.C.D. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?. Eur. J. Cancer 2008, 44:175-181.
28. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17(Suppl 1):S112-118.
29. Khan S.S., Smith M.S., Reda D., Suffredini A.F., McCoy J.P. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry Part B: Clinical Cytometry 2004, 61B:35-39.
30. Kurz K., Fiegl M., Holzner B., Giesinger J., Pircher M., Weiss G., Denz H.A., Fuchs D. Fatigue in patients with lung cancer is related with accelerated tryptophan breakdown. PLoS One 2012, 7:e36956.
31. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001, 92:1684-1688.
32. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D., DeGeest K., Costanzo E.S., Henderson P.J., Sephton S.E., Rohleder N., Lucci J.A., Cole S., Sood A.K., Lubaroff D.M. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 2008, 26:4820-4827.
33. Maes M. The cytokine hypothesis of depression: inflammation, oxidative and nitrosative stress (IO and NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett. 2008, 29:287-291.
34. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:702-721.
35. Malekzadeh A., de Groot V., Beckerman H., van Oosten B.W., Blankenstein M.A., Teunissen C. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 2012, 56:508-513.
36. Meeusen R., Watson P., Hasegawa H., Roelands B., Piacentini M.F. Central fatigue: the serotonin hypothesis and beyond. Sports Med. 2006, 36:881-909.
37. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
38. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26:971-982.
39. Minton O., Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann. Oncol. 2009, 20:17-25.
40. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P.C. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J. Pain Symptom Manage. 2011, 41:761-767.
41. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
42. Myers G.L., Rifai N., Tracy R.P., Roberts W.L., Alexander R.W., Biasucci L.M., Catravas J.D., Cole T.G., Cooper G.R., Khan B.V., Kimberly M.M., Stein E.A., Taubert K.A., Warnick G.R., Waymack P.P. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation 2004, 110:e545-e549.
43. Mykletun A., Stordal E., Dahl A.A. Hospital anxiety and depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br. J. Psychiatry 2001, 179:540-544.
44. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
45. Orre I.J., Reinertsen K.V., Aukrust P., Dahl A.A., Fosså S.D., Ueland T., Murison R. Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. J. Psychosom. Res. 2011, 71:136-141.
46. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 1994, 40:288-295.
47. Payne J.K. A neuroendocrine-based regulatory fatigue model. Biol. Res. Nursing 2004, 6:141-150.
48. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Investig. 2003, 111:1805-1812.
49. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
50. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
51. Rassoulpour A., Wu H.-Q., Ferre S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 2005, 93:762-765.
52. Reinertsen K.V., Cvancarova M., Loge J.H., Edvardsen H., Wist E., Fossa S.D. Predictors and course of chronic fatigue in long-term breast cancer survivors. J. Cancer Surviv. 2010, 4:404-405.
53. Roscoe J.A., Kaufman M.E., Matteson-Rusby S.E., Palesh O.G., Ryan J.L., Kohli S., Perlis M.L., Morrow G.R. Cancer-related fatigue and sleep disorders. Oncologist 2007, 12:35-42.
54. Russo S., Kema I.P., Bosker F., Haavik J., Korf J. Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications. World J. Biol. Psychiatry 2009, 10:258-268.
55. Ryan J.L., Carroll J.K., Ryan E.P., Mustian K.M., Fiscella K., Morrow G.R. Mechanisms of cancer-related fatigue. Oncologist 2007, 12:22-34.
56. Saligan L.N., Kim H.S. A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav. Immun. 2012, 26:848830-848848.
57. Schroecksnadel K., Fiegl M., Prassl K., Winkler C., Denz H.A., Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J. Cancer Res. Clin. Oncol. 2007, 133:477-485.
58. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
59. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 2002, 303:1-10.
60. Shek D.T., Ma C.M. Longitudinal data analyses using linear mixed models in SPSS: concepts, procedures and illustrations. Sci. World J. 2011, 11:42-76.
61. Shor S. Pathogenesis of chronic fatigue syndrome, a multisystem hypothesis. J. Chronic Fatigue Syndrome 2003, 11:51-68.
62. Singer J.D., Willett J.B. Applied Longitudinal Data Analysis 2003, Oxford Press, New York.
63. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discovery 2002, 1:609-620.
64. Stone P., Hardy J., Huddart R., A'Hern R., Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur. J. Cancer 2000, 36:1134-1141.
65. Stone P., Richards M., A'Hern R., Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann. Oncol. 2000, 11:561-567.
66. Stone P., Richards M., A'Hern R., Hardy J. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J. Pain Symptom Manage. 2001, 22:1007-1015.
67. Swain M.G. Fatigue in chronic disease. Clin. Sci. (Lond) 2000, 99:1-8.
68. Tighe, P., Negm, O., Todd, I., Fairclough, L., 2013. Utility, reliability and reproducibility of immunoassay multiplex kits. Methods 61, 23-29.
69. Von Ah D.M., Kang D.H., Carpenter J.S. Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs. 2008, 31:134-144.
70. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 2002, 5:375-388.
71. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., Fuchs D. Neopterin production, tryptophan degradation, and mental depression - What is the link?. Brain Behav. Immun. 2002, 16:590-595.
72. Wyller V.B., Eriksen H.R., Malterud K. Can sustained arousal explain the chronic fatigue syndrome?. Behav. Brain Funct. 2009, 5:10.
73. Yellen S.B., Cella D.F., Webster K., Blendowski C., Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J. Pain Symptom Manage. 1997, 13:63-74.
74. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.
75. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., Thuret S., Price J., Pariante C.M. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.